Introduction
The application of immunotherapy to treat cancer has acquired increased prominence in the clinical arena within the past decade (1) . The specificity of anti-tumor immune mechanisms and the potential for establishing long-term immunologic memory has placed considerable promise on this strategy over standard surgical, chemotherapeutic, and radiotherapeutic protocols. Within the past year, FDA approval of the first therapeutic cancer vaccine, Sipuleucel-T, has led to increased interest in the expansion of active immunotherapy targeting established malignant disease (7, 8, 12, 30, 31) . Although the indicated use of this therapy is currently limited to patients with asymptomatic or minimally symptomatic metastatic, castrateresistant prostate cancer, alternative applications of this and other similar experimental therapies are being actively explored. Moreover, the employment of Sipuleucel-T immunotherapy contributes to an arsenal of clinically relevant tumor immunotherapeutics that includes numerous monoclonal antibody (MAb) and cytokine therapies (1, 2, 9, 33) . In addition to the role of cancer vaccines as therapeutic agents, prophylactic vaccines have diminished the incidence of infection caused by certain oncogenic and pro-oncogenic microorganisms. The successes of the hepatitis B virus and human papilloma virus vaccines in reducing the occurrence of virallyassociated hepatocellular carcinoma and cervical carcinoma, respectively, clearly demonstrate that vaccines can be used to prevent the onset of cancer.
Simian virus 40 (SV40) is a small, nonenveloped, DNA virus of the Polyomaviridae family. This virus was initially discovered as a contaminant of polio vaccines in the 1960s, and has since been studied extensively due to its ability to transform human and rodent cell lines in vitro (27) . The transforming capacity of SV40 can largely be attributed the virally encoded protein large tumor antigen (Tag), which plays a critical role in viral replication and also 22 23 inactivates host p53 and retinoblastoma family tumor suppressor proteins. While the direct oncogenic potential of SV40 infection has been thoroughly demonstrated in neonatal hamster models (13, 15, 23) , the ability of this virus to promote analogous disease in humans remains
controversial. An association between SV40 and multiple human cancers has been reported via meta-analysis (48) ; however, the validity of such findings has been questioned due to apparent inconsistencies, as well as concerns regarding the specificity of SV40 nucleic acid and protein detection protocols (14, 27) . Interestingly, SV40 appears to have a unique ability to transform human mesothelial cells, and, in conjunction with asbestos, has been identified as a possible cocarcinogen for malignant pleural mesothelioma (4) . Although the precise function of SV40 within the context of human disease remains unclear, this virus (and its individual components) continues to serve as a prototypic model for studies of viral oncogenesis, anti-viral tumor immunity, and polyomavirus biology.
Our laboratory has previously reported on the use of Tag as a model for a representative tumor associated antigen (TAA) to investigate mechanisms of vaccine-induced tumor immunity in a murine model of pulmonary metastasis (51, 52) . Studies performed with recombinant Tag (rTag) vaccination have revealed a number of critical immune components that function within this system, including Tag-specific antibodies (25, 29) , natural killer (NK) cells (24, 26) , and CD8+ T lymphocytes (26) . Additionally, targeted depletion of CD4+ T lymphocytes has demonstrated the importance of this cell population in the immune induction phase (22) , presumably illustrating the 'helper' function that these cells exert in the activation of other antitumor immune effectors. Interestingly, CD4+ 'helper' T lymphocytes were dispensable in the immune effector phase (26) , suggesting that that these cells do not play a necessary role in maintenance of anti-tumor immune effectors post activation. Contrary to the function of CD4+ on October 22, 2017 by guest http://jvi.asm.org/ Downloaded from T lymphocytes, CD8+ T lymphocytes were found to have an important role in the immune effector phase (26), but were not required in the immune induction phase (22) . In addition to components of cell-mediated immunity, production of Tag-specific antibodies strongly correlates with in vivo protection afforded by adaptive anti-tumor immune responses (22, 25, 26, 29) .
Within the context of innate immunity, NK cells and NK cell-activating compounds, such as poly(I:C), have been shown to mediate important immune reactions to Tag-expressing tumor cells (24) . Furthermore, NK cells appear to play a critical role in certain adaptive immune mechanisms, such as antibody-dependent cell-mediated cytotoxicity (ADCC), as targeted NK cell depletion or knockout mutations in activating Fcγ receptors (FcγRI, FcγRIII) render mice susceptible to tumor formation (25, 26) .
Although most of our studies have focused on anti-tumor immune mechanisms induced upon rTag vaccination, we have also previously reported on the construction and protective efficacy of two novel Tag DNA vaccines, designated pSV3-neo and pCMV-Tag (6, 29) . In a 2005 study performed by our laboratory, pCMV-Tag was found to express substantially higher levels of Tag than pSV3-neo, and was shown to protect mice against intravenous (i.v.) challenge with an SV40 transformed tumor cell line, designated mKSA (29) . Protective immunity appeared to correlate with the induction Tag-specific antibody responses and the production of Th1-promoting cytokines, such as IL-2. Aside from our own observations, many other groups have commented on the proclivity for DNA vaccines to elicit Th1-skewed immune responses, particularly within the context of neonatal immunization (32, 44, 50) . In these reports, genetic immunization of newborn mice was successful in breaking Th2-associated tolerance to distinct viral antigens, and was typified by induction of Th1-promoting cytokines, IgG2a production, and generation of CD8+ cytotoxic T lymphocytes (CTLs). Importantly, one of these reports also indicated an enhancement of in vivo protection to Cas-Br-M murine leukemia virus in response to immunization with plasmid DNA (44) . Although characterization of DNA vaccine-induced tumor immunity has been reported for other virus-associated tumor antigens, such as HPV E6 and E7 (17, 39) , to our knowledge, the mechanisms of DNA-vaccine induced tumor immunity directed towards SV40 Tag have not been elucidated.
In this report, we extend our previous studies by characterizing the immune components necessary for the protective function of pCMV-Tag. An initial vaccine titration experiment was employed to corroborate in vivo protection with the development of Tag-specific antibody responses, and targeted depletion of T lymphocyte subsets was subsequently performed to assess the role of cell-mediated immunity in the induction and effector immune phases. In all experiments, mice were immunized with pCMV-Tag prior to challenge with mKSA tumor cells, and in vivo protection was determined by quantification of tumor foci in mouse lungs. 
Materials and Methods

Cells and media
Tumor challenge studies were performed in vivo using the SV40-transformed BALB/c mouse kidney fibrosarcoma cell line mKSA. Cells were cultured in Dulbecco's modified Eagle's medium containing L-glutamine (HyClone, Logan, UT), and supplemented with 0.1 mM nonessential amino acids (Sigma, St. Loius, MO), 100 U/ml penicillin (Sigma), 500 µg/ml streptomycin (Sigma), and 10% heat-inactivated fetal bovine serum (HyClone). Prior to in vivo administration, cells were detached from flasks with 1 mM EDTA-phosphate-buffered saline (PBS), washed in PBS, and adjusted to 1 X 10 5 cells in a total volume of 50 µl sterile PBS.
In vivo depletion of T lymphocytes
Depletion of murine CD4+ and CD8+ T lymphocytes was performed in vivo using the rat IgG2b MAbs GK1.5 and 2.43, respectively. Depletion reagents were purified using a mouse anti-rat antibody affinity column, and the total protein content was estimated by measuring absorbance at 280 nm. The purified rat IgG MAbs and a control rat IgG preparation were adjusted to 100 µg in 0.1 ml, and administered to mice a total of 3-6 times via intraperitoneal injection. Depletion schemes for induction phase and effector phase studies are detailed in Fig.   1 .
Flow cytometry was performed to assess the efficacy of T cell depletion, using rat antimouse MAbs for CD4 (clone RM4-5) (BD Biosciences, Franklin Lakes, NJ) and CD8 (clone YTS169.4) (BD Biosciences), as described previously (22) . Relative to untreated and rat IgGtreated control mice, >95% of CD4+ and CD8+ T cell populations were depleted (data not shown). 
Tag ELISA
Mouse immune sera were screened for IgG antibodies to Tag via indirect ELISA, as described previously by our laboratory (29) . Briefly, 200 ng rTag in PBS was coated onto the solid phase of a 96-well microtiter plate and incubated at 37°C for one hour. Non-specific binding was blocked by addition of 0.2% porcine gelatin in 0.05% PBS-tween, followed by incubation of plates at 37°C for 30 minutes. Plates were washed in PBS-tween, and dilutions of mouse sera were added and incubated at 37°C for one hour. Plates were washed again in PBStween, and samples were probed via incubation with a horseradish peroxidase (HRP)-labeled goat anti-mouse IgG (γ chain) reagent (1:5,000) at 37°C for 30 minutes. Plates were washed a final time, developed via addition of TMB peroxidase substrate (KPL, Inc., Gaithersburg, MD), and the reaction was terminated after ~5 minutes by addition of 1M H 3 PO 4 . An optical density (OD) value at 450 nm that was at least three times the OD value for pre-immune sera was employed as a cutoff value for positive reactivity. All samples were tested in triplicate, and appropriate positive and negative control MAbs to SV40 Tag (PAb 405 and A1.2, respectively)
were used to assure functionality of the assay.
In some experiments, IgG subtyping of mouse immune sera was performed to assess the Th1 versus Th2 proclivity of DNA vaccine-induced immunity (46) . A modification of the indirect ELISA was employed to detect IgG subtypes, as described previously by our laboratory (24) . Briefly, samples were incubated with rabbit anti-mouse reagents specific for IgG1 and IgG2a (Bio-Rad, Hercules, CA) for one hour at 37°C following the serum binding step. An HRP-labeled goat anti-rabbit IgG reagent (1:1,000) (KPL, Inc.) was used to probe the samples, and development was performed as described above. The Tag-specific MAbs PAb 405 and PAb 419 were used as controls for mouse IgG1 and IgG2a, respectively, and to assess any crossreactivity between subtyping reagents.
Statistical analysis
In all animal experiments, lung tumor focus values were logarithmically transformed, and statistical assessment between groups was performed by one-way analysis of variance (ANOVA)
followed by the Tukey-Kramer multiple comparisons test. Statistical significance between groups was detailed at P <0.05 or P <0.01, and is indicated accordingly in the corresponding figures. All statistical analyses were performed using GraphPad InStat® and Prism® software. 
Immunization with pCVM-Tag induces a mixed IgG subtype distribution to SV40 Tag
In order to assess the Th1 versus Th2 proclivity of the antibody response induced upon (Fig. 3, 1' group) . Two immunizations with pCMV-Tag completely abolished tumor formation in mouse lungs (Fig. 3, 2' group) . Complete protection from lung tumor focus development was also observed through three and four injections of pCMV-Tag (Fig. 3, 3' and 4' groups) . In contrast, successive immunizations with pcDNA3.1 failed to abolish the tumor burden in mouse lungs (Fig. 3, 2 '-4' groups). 
Depletion of CD8+ T lymphocytes shifts the immune response towards enhanced antibody production to SV40 Tag
Previous studies by our laboratory have indicated that depletion of certain lymphocyte subsets can influence the subsequent antibody response to SV40 Tag (22) . Specifically, mice depleted of CD4+ T lymphocytes in the immune induction phase were unable to mount an antibody response to rTag, and were susceptible to lung tumor foci formation upon challenge with mKSA tumor cells. In order to assess the impact of induction phase T cell depletion on antibody responses stimulated by pCMV-Tag, we assessed the titers of Tag-specific mouse IgG during the course of the depletion /immunization regimen via indirect ELISA. Table 3 provides Tag-specific IgG antibody titers for different murine depletion groups after the primary and secondary injections of plasmid DNA. Consistent with findings from the previous titration experiment, mice immunized with pcDNA3.1 or pCMV-Tag and treated with a control depletion reagent did not exhibit detectable antibody titers after one or two injections of the plasmid DNA. Similarly, mice immunized with pCMV-Tag and treated with an anti-CD4 reagent did not produce detectable antibodies to SV40 Tag. In contrast, all mice immunized with pCMV-Tag and treated with an anti-CD8 reagent generated an antibody response to SV40 Tag after two injections of the plasmid DNA. The mean titer of anti-Tag antibodies produced by these CD8-depleted mice (mean: 860), fell between the titers previously determined for mice immunized with three (Table 1 ; mean: 520) and four (Table 1; 
The critical role of CD4+ T lymphocytes extends to tumor immunity within the immune effector phase
In order to ascertain whether the vital function of CD4+ T lymphocytes extends to the immune effector phase, we immunized mice four times with pCMV-Tag and performed a depletion of CD4+ and CD8+ T lymphocytes at the time of tumor cell challenge. All mice were positive for antibodies to SV40 Tag following the fourth injection of pCMV-Tag, as indicated in Table 1 and previous experiments (29) . Figure 1C 
Discussion
Our laboratory has previously reported on the ability of prophylactically administered rTag to induce protective immune responses in BALB/c mice that were capable of preventing tumor development by the SV40 transformed cell line, mKSA (22, 25, 26) . These studies demonstrated that humoral immune effectors (e.g., antibodies to SV40 Tag, CD4+ T lymphocytes), components of cell-mediated immunity (e.g., CD4+ T lymphocytes, CD8+ T lymphocytes), and innate immunity (e.g. NK cells) were all required for the elicitation of complete tumor immunity. We proposed that CD4+ T lymphocytes functioned within a Th2-like Given our previous finding that CD8+ T lymphocytes execute essential immune functions in the immune effector phase, and our recent discovery that tumor immunity could be achieved prior to antibody production, we thought it pertinent to investigate the role of these cells within the context of pCMV-Tag-induced tumor immunity. Surprisingly, targeted depletion of CD8+ T lymphocytes showed that these cells are not required in either the induction or effector immune phases generated via vaccination with pCMV-Tag. This phenomenon can perhaps be attributed to the severely limited panel of Tag epitopes capable of recognition by CD8+ T lymphocytes from BALB/c mice (35, 41) . Additionally, depletion of CD8+ T lymphocytes appears to engage compensatory effector mechanisms within the anti-tumor immune response, as evidence by enhanced antibody production in the induction immune phase.
Despite the expendability of CD8+ T lymphocytes in these experiments, other studies performed by our laboratory clearly indicate that certain Th1-driven components of cell-mediated immunity are beneficial to tumor inhibition within our model (24) . Recent studies on the role of the innate In contrast to the roles of antibody and CD8+ T lymphocytes, CD4+ T lymphocytes were required at all stages of the immune response to effect complete tumor immunity to mKSA tumor cells. Although we cannot, at present, ascribe a definitive mechanism of action for CD4+
T lymphocytes in our model, multiple roles for CD4+ T lymphocytes have been identified within the context of murine and human tumor immunity. Such roles include the provision of 'help' to CD8+ T lymphocytes and antibody-secreting cells, direct cytotoxic functions, and the regulation of the immune axis through secretion of immunoregulatory cytokines (20, 38, 47) . In this study, (11), but were not associated with direct cell-mediated cytotoxicity (11, 19) . Additionally, β2-microglobulin knockout mice were capable of controlling infection to M. tuberculosis upon immunization with plasmid DNA, providing evidence that protective immunity was independent of CD8+ CTLs 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43 pCMV-Tag + anti-CD8 <50 860 200) Mouse sera were obtained for various depletion groups 14 days post first and second immunization with pcDNA3.1 or pCMV-Tag, and antibody titers to SV40 Tag were determined via indirect ELISA, as described in 
